Excessive aortic inflammation in chronic obstructive pulmonary disease: An 18F-FDG PET pilot study

Journal of Nuclear Medicine

Volumn 51, Issue 9, 2010, Pages 1357-1360

  Coulson, James M ^a   Rudd, James H F ^b   Duckers, James M ^a   Rees, John I S ^c   Shale, Dennis J ^a   Bolton, Charlotte E ^a,d   Cockcroft, John R ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Imaging; Inflammation; Vessel

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ABDOMINAL AORTA; AGED; AORTA ARCH; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; HEMODYNAMIC PARAMETERS; HUMAN; IMAGE ANALYSIS; MALE; METABOLIC SYNDROME X; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPIROMETRY; VASCULITIS; AORTA; ARTERITIS; CLINICAL TRIAL; MIDDLE AGED; SCINTISCANNING; SMOKING;

AGED; AORTA; ARTERITIS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 77957096499     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.075903     Document Type: Article

References (20)

1. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62:411-415.
2. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952-1959.
3. Bolton CE, Ionescu AA, Shiels K, et al. Associated loss of fat free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:1286-1293. (Pubitemid 39657192)
4. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580. (Pubitemid 38901515)
5. Bolton CE, Evans M, Ionescu AA, et al. Insulin resistance and inflammation: a further systemic complication of COPD. COPD. 2007;4:121-126. (Pubitemid 47164861)
6. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:1259-1265. (Pubitemid 46905751)
7. 18F- fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-1824.
8. 18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-2711.
9. Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2:107-115.
10. 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008;49:1277-1282.
11. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation. J Am Coll Cardiol. 2006;48:1825-1831.
12. 18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49:1533-1539.
13. Graebe M, Pedersen S, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission topography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714-721.
14. Pedersen SF, Graebe M, Fisker Hag AM, Højgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31:423-429.
15. 18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors: correlation in a PET-CT study. Nuklearmedizin. June 8, 2010 [Epub ahead of print].
16. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209-217. (Pubitemid 351396317)
17. Rudd JHF, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography. J Am Coll Cardiol. 2010;55:2527-2535.
18. Yuri Sheikinea Y, Akramc K. FDG-PET imaging of atherosclerosis: do we know what we see? Atherosclerosis. February 1, 2010 [Epub ahead of print].
19. 123I-metaiodobenzylguanidine. J Nucl Med. 2003;44:1747-1754.
20. 13N PET as a vascular biomarker in chronic obstructive pulmonary disease. J Nucl Med. 2010;51:57-65.